Bio-Path Holdings
Houston
About Bio-Path Holdings
Bio-Path is a biotechnology company developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $57.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2024)
- Ticker: nasdaq:BPTH
- Website: biopathholdings.com
- Phone: (832)971-6616
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/bio-path-holdings-119061 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.